Deborah Ramsdell
Chief Executive Officer at Valerion Therapeutics LLC
Profile
Deborah Ramsdell is currently the President, Chief Executive Officer & Director at Valerion Therapeutics LLC.
She is also the President, Chief Executive Officer & Director at Phoenicis Therapeutics, Inc. Additionally, she holds the position of Director at Orphan Technologies Ltd.
and is the VP-Development Operations & Regulatory Affairs at Alopexx Enterprises LLC.
Ms. Ramsdell has previously worked as the President & Chief Executive Officer at Wings Therapeutics, Inc. She has also held positions as the Director-Regulatory Affairs & Quality Assurance at ImmunoGen, Inc. and Virus Research Institute, Inc. Furthermore, she has worked as the Principal at Biotechnica International, Inc. and as the VP-Regulatory Affairs & Clinical Operations at both Alexion Pharmaceuticals, Inc. and Enobia Pharma, Inc. Ms. Ramsdell completed her undergraduate and graduate degrees at Boston College.
Deborah Ramsdell active positions
Companies | Position | Start |
---|---|---|
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA. | Chief Executive Officer | - |
Alopexx Enterprises LLC
Alopexx Enterprises LLC BiotechnologyHealth Technology Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA. | General Counsel | 2010-12-31 |
Orphan Technologies Ltd.
Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Director/Board Member | 2015-01-31 |
Phoenicis Therapeutics, Inc.
Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Chief Executive Officer | - |
Former positions of Deborah Ramsdell
Companies | Position | End |
---|---|---|
Wings Therapeutics, Inc.
Wings Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wings Therapeutics, Inc. engages in the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa. The company was founded in 2019 and is headquartered in Berkeley, CA. | Chief Executive Officer | - |
ALEXION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | General Counsel | - |
Biotechnica International, Inc.
Biotechnica International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Groupe Limagrain Holding SA, Biotechnica International, Inc. is a company that specializes in agricultural research. The company is based in Shawnee Mission, KS. | Corporate Officer/Principal | - |
IMMUNOGEN, INC. | General Counsel | - |
Training of Deborah Ramsdell
Boston College | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 10 |
---|---|
Virus Research Institute, Inc.
Virus Research Institute, Inc. BiotechnologyHealth Technology Part of Celldex Therapeutics, Inc., Virus Research Institute, Inc. develops systems for the delivery of vaccines. The company is based in Cambridge, MA. | Health Technology |
ImmunoGen, Inc.
ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Biotechnica International, Inc.
Biotechnica International, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Groupe Limagrain Holding SA, Biotechnica International, Inc. is a company that specializes in agricultural research. The company is based in Shawnee Mission, KS. | Commercial Services |
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Valerion Therapeutics LLC
Valerion Therapeutics LLC Medical SpecialtiesHealth Technology Valerion Therapeutics LLC develops targeted therapies for orphan genetic diseases. The firm utilizes a proprietary antibody-mediated delivery platform to target therapies to specific tissues via a studied transport pathway. It therapies are based on an intracellular delivery technology platform that takes advantage of tissue targeting via an antibody and intracellular delivery dependent on membrane expression of a nucleoside transporter. The company was founded by Timothy S. Harris and Dustin D. Armstrong in 2007 and is headquartered in Concord, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Alopexx Enterprises LLC
Alopexx Enterprises LLC BiotechnologyHealth Technology Alopexx Enterprises LLC engages in investing and managing health care companies. It develops medical therapies and devices for infectious diseases, oncology, central nervous system, and orphan diseases. The firm commercializes an alternative for the treatment and prevention of staphylococcal and other bacterial infections and animal vaccines. The company was founded by Daniel R. Vlock, Deborah Ramsdell and Christine de los Reyes in 2011 and is headquartered in Concord, MA. | Health Technology |
Wings Therapeutics, Inc.
Wings Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wings Therapeutics, Inc. engages in the development of transformational therapies for patients that suffer from Dystrophic Epidermolysis Bullosa. The company was founded in 2019 and is headquartered in Berkeley, CA. | Health Technology |
Orphan Technologies Ltd.
Orphan Technologies Ltd. Pharmaceuticals: MajorHealth Technology Orphan Technologies Ltd. engages in the manufacturing of biopharmaceutical drugs. It develops novel therapies for patients suffering from rare disorder and classical homocystinuria. The company is headquartered in Rapperswil, Switzerland. | Health Technology |
Phoenicis Therapeutics, Inc.
Phoenicis Therapeutics, Inc. BiotechnologyHealth Technology Phoenicis Therapeutics, Inc. is a private company that is focused on developing therapies for rare dermatological disorders. The company is based in Hingham, MA. The company's goal is to improve the lives of those who suffer from these conditions. The CEO of the company is Deborah Ramsdell. | Health Technology |
- Stock Market
- Insiders
- Deborah Ramsdell